Importantly, most SMARCA4-deficient tumors demonstrated a clearly differentiated phenotype, either adenocarcinoma or SCC, suggesting that loss of SMARCA4 in NSCLC is a primary genetic driver event, in contrast to endometrial carcinomas, where it results from a second or third hit and leads to dedifferentiation. This evidence concerns the gene SMARCA4 and endometrial carcinoma.